PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells

Sorafenib, a multi-kinase inhibitor, is the first-line treatment for advanced hepatocellular carcinoma (HCC) patients. However, this drug only provides a short improvement of patients’ overall survival, and drug resistance is commonly developed. Thus, the identification of resistant factor(s) or bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jiunn-Chang, Yang, Pei-Ming, Liu, Tsang-Pai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199104/
https://www.ncbi.nlm.nih.gov/pubmed/34072570
http://dx.doi.org/10.3390/ijms22115848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199104/
https://www.ncbi.nlm.nih.gov/pubmed/34072570
http://dx.doi.org/10.3390/ijms22115848

Ejemplares similares